Skip to main
PCVX
PCVX logo

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. displays a positive financial outlook driven by the strong performance of its product candidates, particularly VAX-24 and VAX-31, which have shown superior immune responses compared to the current standard, PCV20, in adult populations. The company anticipates a significant mid- to long-term growth opportunity, estimating a global revenue potential exceeding $7-10 billion, supported by ongoing clinical trials that showcase robust seroresponse rates in both infants and adults. Additionally, the ongoing positive clinical data, especially regarding VAX-24 in infants, positions Vaxcyte favorably against its competitors in the next-generation pneumococcal vaccine market.

Bears say

The analysis highlights several fundamental risks associated with Vaxcyte Inc., primarily stemming from potential delays in research and development, regulatory hurdles, and disappointing clinical trial outcomes that could negatively impact efficacy or safety results. Additionally, the firm's commercial uptake may be stunted due to competition, particularly if competitor programs advance more quickly than Vaxcyte's offerings, which could hinder market position. Furthermore, despite the company's projected long-term revenue potential, any lack of alignment with national vaccine guidelines or failures in proving the safety and efficacy of its vaccine candidates in trials could significantly limit the company's commercial prospects.

Vaxcyte (PCVX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.